A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)
Study Identifier:
ECU-MG-303
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Eculizumab
Date
Dec 2018 - Jan 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A
Requirements Information
Sex
Female & Male
Age
N/A - N/A
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Eculizumab
Date
Dec 2018 - Jan 2022
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: N/A - N/A years
Requirements Information
Protocol Summary
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of eculizumab in the treatment of pediatric refractory gMG based on change from Baseline in the Quantitative Myasthenia Gravis (QMG) score for disease severity.
Trial Locations
Location
Status
Location
Research Site
Los Angeles, California, United States, 90078
Status
N/A
Location
Research Site
Tampa, Florida, United States, 33612
Status
N/A
Location
Research Site
Chicago, Illinois, United States, 60611
Status
N/A
Location
Research Site
Columbia, Missouri, United States, 65201
Status
N/A
Location
Research Site
Chapel Hill, North Carolina, United States, 27599
Status
N/A
Location
Research Site
Akron, Ohio, United States, 44308
Status
N/A